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1. Introduction 
Pulmonary edema (PE) remains one of the more common reasons for admission to the 
hospital. Pulmonary edema is either cardiac or non-cardiac. The cardiac causes of 
pulmonary edema occur because the cardiac pump function has failed and there is increased 
capillary hydrostatic pressure secondary to elevated pulmonary venous pressure. 
Cardiogenic pulmonary edema is the accumulation of fluid with a low-protein content in 
the lung interstitium and alveoli and occurs when the pulmonary venous and left atrial 
venous return exceeds left ventricular output. Most often this is due to left heart failure, 
cardiac valve disease, volume overload, kidney failure or cardiac tamponade. Non 
cardiogenic pulmonary edema (NCPE) is a condition that is associated with high morbidity 
and mortality. Pulmonary edema fluid accumulates in the lungs through damaged capillary 
endothelial cells and this leads to impaired gas exchange (oxygen and carbon dioxide) with 
hypoxia and respiratory failure. The best example of non-cardiogenic pulmonary edema is 
acute respiratory distress syndrome (ARDS) (Sartori et al, 2010). ARDS is a serious condition 
of hypoxia, bilateral lung infiltrates on chest roentgenogram with subsequent respiratory 
failure. The hallmark of ALI (acute lung injury)/ARDS on the cellular level is pulmonary 
capillary endothelial cell permeability and fluid leakage into the pulmonary parenchyma, 
followed by neutrophils, cytokines and an acute inflammatory response. It is associated 
with a high morbidity and 30-50% mortality. ARDS has multiple causes with the most 
common being sepsis or pneumonia, less common causes of ARDS with ensuing pulmonary 
edema are trauma or pancreatitis (Ware & Mathay, 2005). Other causes of NCPE in 
hospitalized patients are intravenous fluid with volume overload, neurogenic pulmonary 
edema, reperfusion pulmonary edema, re-expansion pulmonary edema, opiate overdose, 
salicylate toxicity. Less common, forms of NCPE are high altitude pulmonary edema 
(HAPE), immersion pulmonary edema and negative pressure pulmonary edema (NPPE).  
2. Increased permeability pulmonary edema 
NCPE causes direct injury to the lungs in several forms. Under normal conditions fluid 
outflow that occurs from the lung capillaries through tiny gaps in the vascular endothelial 
cell (EC) junction is removed from the interstitial space and returned to the circulation by 
the lymphatic system. Physiologically, the main forces regulating fluid balance in the lungs 
are the microvascular pressure of the capillaries. Fluid leaves the capillaries and enters the 
pulmonary interstitium in proportion to the net capillary hydrostatic pressure minus the net 
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osmotic pressure across the vessel wall. The formula for filtration across the pulmonary 
capillary semi-permeable membrane is  
Q=K-[CPmv-Ppmv)-(πmv-πpmv)] 
which is different from the systemic capillary fluid exchange. Q=net transvascular flow of 
fluid, K=membrane permeability, Pmv=hydrostatic pressure in the microvessels, 
Ppmv=hydrostatic pressure in the peri-microvascular interstitium, πmv=plasma protein 
osmotic pressure in the circulation, πpmv=protein osmotic pressure in the peri-
microvascular interstitium. This equation only reflects the known hydrostatic pressures 
without including the lymph hydrostatic pressure which has been studied but is unknown 
in relation to the Starling forces equation (Sartori et al, 2010). It is known that one of the 
main functions of the lymphatic system is to return plasma proteins from the interstitial 
tissue space to the bloodstream. Analyses of blood plasma and lymph have shown that all of 
the proteins that are found in the plasma are also found in the lymph although in lower 
concentrations (Ono et al, 2005). In normal circumstances, low pulmonary capillary 




Fig. 1. Representation of the pulmonary arterial and venous capillary barrier and lymphatic 
flow.  
Although hydrostatic pressures in the pulmonary arterial and venous system are known, 
the hydrostatic pressures of the interrelated pulmonary lymphatic system is unknown and 
largely unstudied. The illustration generously permitted by Dr. Davide Brunelli of Med-
ars.it. 
In some forms of NCPE such as ARDS disturbances of pulmonary capillary fluid balance 
and pulmonary permeability occur as a direct result of endotoxins and inflammation that 
cause disruption in the capillary EC barrier with barrier disruption and subsequent 
pulmonary venous congestion. As the volume excess initially enters the interstitium it is 
taken up by the lymphatic system to be returned to the vascular system. In normal 
circumstances the interstitial space can increase its volume by as much as 40% without 
resulting in pulmonary edema (Sartori et al, 2010). In pulmonary injury due to toxins or 
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inflammation the fluid volume increase overwhelms the lymphatic drainage system and the 
hydrostatic forces become altered resulting in further injury to the pulmonary capillary 
endothelium. The result is persistent fluid accumulation that overwhelms the lymphatic 
drainage and tissue edema results. The final step occurs as the fluid volume overwhelms the 
hydrostatic forces and the excess fluid flows into the alveoli. The edema that is caused by 
the increasing fluid and vascular permeability is a hallmark of inflammation and tissue 
injury (Zimmerman & McIntyre, 2004). The edema formation can have severe consequences 
because the fluid and protein components in the edematous tissues and alveoli increase the 
diffusion barrier for oxygen and carbon dioxide with subsequent disruption of gas exchange 
thus precipitating hypoxia and respiratory failure. The rate of volume expansion is also a 
factor in pulmonary edema.  
Other forms of NCPE such as HAPE, immersion pulmonary edema and NPPE may occur 
due to greatly altered thoracic pressures and are thought to have a largely hydrostatic non-
inflammatory component (Fremont et al, 2007). The accelerated pulmonary edema that 
occurs with HAPE, immersion PE or NPPE is thought to be due to significant fluid shifts 
that come secondary to changes in intrathoracic pressure, and in the case of HAPE or 
immersion PE, possibly due to diminished atmospheric or oxygen inhalation pressures. 
Physiologically negative intrathoracic pressure is generated in the chest when a patient 
inspires against an obstructed airway. The rapid pressure change in the pulmonary venous 
circulation alters the transpulmonary fluid gradient. The increase in capillary hydrostatic 
pressure most likely causes capillary gap formation as well as transcellular fluid shifts. The 
fluid gradient is thus going from a high gradient to a low gradient. Although considered a 
second mechanism of the EC barrier disruption it is part of the capillary hydrostatic 
pressure. While it is unlikely that the rapidly resolved post obstructive PE and HAPE are of 
a different nature, it is more likely that all of the non-cardiogenic PE have the same 
hydrostatic mechanisms initially (Sartori et al, 2010 & Gantor et al, 2006). The NCPE in 
ARDS is ultimately a result of capillary permeability secondary to cellular damage, 
inflammatory cascades, and over inflation by mechanical ventilation resulting in endothelial 
permeability. The permeability from HAPE and scuba diving is not initiated by 
inflammation but rather stress failure occurring due to the increased pressures that occur at 
the capillary level in healthy subjects (Slade et al, 2001). The pulmonary capillary endothelial 
cell barrier is a semi-permeable membrane and is known to be an active biological interface 
between the blood and the surrounding tissue. The EC is a single layer of continuous 
endothelium lining the pulmonary capillaries and forms a single layer between blood and 
the pulmonary interstitium. The pulmonary capillaries have extremely thin walls to allow 
rapid exchange of respiratory gases across them (Costello et al, 1992).The endothelium 
modulates tone, growth, homeostasis and inflammation in the lungs and throughout the 
circulatory system (Ware & Matthay, 2005 & Umapathy et al, 2010). In NCPE due to diseases 
such as ARDS, the ensuing endotoxins and inflammatory markers induce capillary 
endothelial disarray and gap formations. This is followed by neutrophil chemotaxis, 
diapedesis and protein rich edema fluid leakage into the interstitial spaces. Inflammatory 
cascades are triggered and also enter into the interstitial milieu. As the capillary pressure 
increases there is damage of the capillary EC causing larger molecules such as proteins from 
the vascular space to flow into the interstitial space (Slade et al, 2001). NCPE in an ill patient 
with ARDS is a high protein pulmonary edema. The fluid/plasma ratio may be used to 
differentiate the etiology of pulmonary edema in NCPE and CPE. It is a measurement of the 
alveolar fluid, obtained by broncho- alveolar lavage (BAL), to the serum plasma during 
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acute pulmonary edema and has been shown in studies to be sensitive enough to 
differentiate a low protein fluid that results from CPE or NCPE in a patient without illness 
compared to a high protein ratio NCPE such as occurs with illness such as endotoxin 
induced ARDS (Fremont et al, 2001; Ware et al, 2010). The protein concentration in the 
pulmonary interstitium of ARDS exceeds 60% of the plasma value whereas the protein 
concentration in HAPE, reperfusion PE, neurogenic PE and other non ARDS causes is less 
than 45% (Fein et al, 1079 & Staub et al, 1967). The result is capillary injury with gap 
formation and high permeability of the EC barrier with an increase of protein rich edema 
fluid into the interstitial space. The resulting pulmonary interstitial protein remains elevated 
compared to circulating blood plasma. At this point there is no longer a “quick” resolution 
possible.  
 
Fig. 2. Schematic representation of the endothelial barrier in inflammatory pulmonary 
edema.  
NCPE causes direct injury to the lungs. The endothelial barrier is normally single layer of 
continuous endothelium lining the pulmonary capillaries. In ALI/ARDS the endotoxins 
recruited by the macrophages and neutrophils induce capillary endothelial disarray and gap 
formations. This is followed by neutrophil chemotaxis, diapedesis, proteases, cytokines and 
protein rich fluid into the interstitial spaces. 
3.  Neutrophils and molecular mechanisms in the endothelial and epithelial 
cell barrier in ALI/ARDS 
Neutrophils play an important role in the development of pulmonary edema associated 
with ALI/ARDS. It is well known that neutrophils are prevalent in ARDS pulmonary 
edema and are central to the pathogenesis (Bdeir et al, 2010). Initially pulmonary 
macrophages are activated and recruit circulating neutrophils to the pulmonary 
microvascular system and the injured capillaries. The interaction of the neutrophils and the 
endothelium is initiated by adhesion receptors and by soluble or membrane bound 
chemoattractants. Intercellular adhesion molecules-1 (ICAM-1) and other proteins are 
known to be present but the specific role of these molecules and proteins is unclear 
(Downey et al, 1999). Once the neutrophils become activated and move subsequently into 
the pulmonary parenchymal interstitium, they sequester and initiate an important 
component of the inflammatory response in endotoxin induced ALI/ARDS. This activation 
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and migration of neutrophils is a characteristic event in the progression of ALI and ARDS. 
Animal studies have shown that endothelial injury appears within minutes to hours after 
ALI initiation with resulting intercellular gaps of the EC. The EC gaps allow for 
permeability of fluid, neutrophils and cytokines into the pulmonary parenchymal space 
(Grommes & Soehnlein, 2011).  
The neutrophils that infiltrate the lungs and migrate into the airways express pro-
inflammatory cytokines such as TNF-ǂ, IL-1ǃ, IL-6 and contribute to both the endothelial 
and epithelial integrity disruption of the barriers (Bdeir et al, 2010; Grommes & Soehnlein, 
2011; Abraham, 2003). It has also been well documented that the percentage of neutrophils 
correlates directly with the alveolar-arterial PO2 difference in ALI/ARDS pulmonary edema 
(Weiland et al, 1986). Neutrophil sequestration is aided by chemotactic factors and by the 
adhesion molecules on both the neutrophils and capillary endothelial cells (Hasko et al, 
2006; Steinberg, 1994; Geerts et al, 2001). The activated neutrophils expressing IL-1ǃ produce 
other pro-inflammatory cytokines after endotoxin administration. In fact, the removal of 
neutrophils after endotoxin administration almost entirely prevents an increase of IL-1ǃ 
expression and attenuates endotoxin induced TNF-ǂ. Neutrophils are the major source of 
IL-1ǃ in murine models of the lung in ALI (Abraham, 2003). Another feature of the 
neutrophils that accumulate in the lung of murine models is increased activation of the 
transcriptional regulatory factor NF-кB. NF-кB is a protein complex that controls 
transcription of DNA and is involved in cellular responses to stimuli such as pulmonary 
edema due to ALI/ARDS. It is key in regulating the endotoxin induced immune response in 
neutrophils and produces increased amounts of pro-inflammatory cytokines whose 
transcription is dependent on NF-кB (Blackwell et al, 1996). Neutrophils also become an 
increasing liability in the edematous pulmonary interstitium as they release free radicals. 
The alveolar-capillary barrier is a very thin membrane allowing oxygen CO2 exchange for 
normal respiration. The major consequence of pulmonary edema is impaired gas exchange 
that interrupts the normal fluid exchange balance. The alveoli epithelium removes fluid by 
molecular mechanisms of sodium transport, however, the capillary endothelial barrier 
function has only incompletely defined pathways affecting the concurrent barrier 
disruption. Permeability of the EC in the capillaries with concurrent alveolar-capillary 
membrane damage and with leakage of fluid, neutrophils, proteases, cytokines and free 
radicals that all contribute to the ensuing pulmonary edema is a prominent feature of 
permeability edema and ALI/ARDS (Holter et al, 1986). The alveolar liquid clearance from 
the alveolus into the interstitium is based on active sodium transport largely through the 
highly regulated apical amiloride sensitive epithelial sodium channel complex (ENaC) with 
concomitant passive water transport and the Na+, K+ ATPase exchange (Elia et al, 2003; 
Folkesson & Matthay, 2006). The Na+, K+ ATPase exchange transports the alveolar liquid 
into the interstitium and ultimately into the lymphatic and blood vessels (Hamacher et al, 
2010; Lucas et al, 2009). However, these transport processes are often impaired in ALI or 
ARDS. 
It is likely that the induction of increased permeability of the pulmonary capillary bed is 
directly linked to reversible physical modifications of the pulmonary capillary endothelium 
(Kaner et al, 2000). The capillary endothelial regulation of endothelial permeability involves 
various pathways such as those involving reactive oxygen species (ROS), Rho GTPases, and 
tyrosine phosphorylation of junctional proteins all converge to regulate junctional 
permeability. They either affect the stability of junctional proteins or modulate their 
interactions (Lucas et al, 2009). The regulation of permeability at the junctions is mediated 
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by active communication between the proteins of the adherens junctions and the actin 
cytoskeleton. Actin mediated endothelial cell contraction is the result of myosin light chain 
(MLC) phosphorylation by MLC kinase (MLCK) in Ca2+/calmodulin- dependent manner. 
RhoA also potentiates MLC phosphorylation by inhibiting MLC phosphatase activity 
through its downstream effector Rho kinase (ROCK). As the actin/myosin driven 
contraction generates a contractile force it pulls VE-cadherin inward. This contraction will 
force VE-cadherin to dissociate from its adjacent partner causing endothelial gaps - the basic 
pathology in permeability pulmonary edema (Lucas et al, 2009).  
4. Serum Biomarkers in permeability edema and ARDS 
A complex progression of events is recognized in the development of permeability edema 
and ARDS but the exact nature of events is still an area of active study. A large variety of 
inflammatory mediators have been found to be elevated in ARDS including lung specific 
proteins, endotoxin binding proteins, tumor necrosis factor alpha (TNF-ǂ), interleukins 
(ILs), chemokines and markers of endothelium activation such as adhesion molecules and 
von Willebrand factor antigen (VWF) (Tzouvelekis et al, 2005). A comprehensive review is 
beyond the scope of this article but some of the most widely known are discussed. There is 
an increased expression of the vascular endothelial growth factor VEGF gene in pulmonary 
edema. Although VEGF is widely expressed in the body, the highest level of expression in 
normal tissues is in the lung. Normally increased expression and angiogenesis is associated 
with lung tumors and has been studied as a target for therapy in lung cancer however VEGF 
also is known to stimulate actin stress fiber formation and new focal adhesions in 
endothelial cells suggesting a regulatory role in endothelial morphology (Kaner et al, 2000). 
A study by Kaner et al demonstrated that excess expression of VEGF within the murine lung 
was associated with increased permeability of pulmonary edema (Kaner et al, 2000). In 
addition to endotoxin effects on endothelial permeability there is strong evidence that 
cytokines such as tumor necrosis factor (TNF-ǂ), interleukin (IL)-1ǃ, IL-6, and IL-8 are 
associated with pulmonary edema. Shutte measured cytokine levels in patients with ARDS, 
severe pneumonia and cardiogenic pulmonary edema for comparison and found 
consistently higher levels of IL-8, IL-6 and TNF-ǂ in the bronchoalveolar lavage fluid 
(BALF) and the serum of patients with ARDS and pneumonia compared to cardiogenic 
pulmonary edema (Schutte et al, 1996). Cytokines have various effects on activating 
endothelium inducing endothelial expression of adhesion molecules and leukocyte 
chemotaxis leading to a local inflammatory response in the lung. The cytokine, TNF-ǂ 
induces macrophages and TH1 cells and activates ECs and macrophages (Braun et al, 2005). 
Studies have been conflicting as far as elevation of TNF-ǂ in patients with ARDS pulmonary 
edema, for example, Bauer demonstrated that TNF-ǂ concentrations were significantly 
higher in patients with ARDS than those of pneumonia or of the control subjects (Bauer et al, 
2000). Others, such as Hyers have found variability in the elevation of TNF-ǂ, however, 
there is speculation that TNF-ǂ is an acute phase cytokine and the timing of studies is 
important for its evaluation (Hyers, 1991). Although Bauer found that the TNF-ǂ levels were 
significantly elevated it was also speculated that the elevation was more related to the 
severity of the lung disease and could not be extrapolated as a possible diagnostic marker 
for ARDS (Bauer et al, 2000). TNF-ǂ is a known acute phase reactant and is also a cytokine 
involved in systemic inflammation. It is able to induce apoptotic cell death, inflammation, 
and inhibit tumorgenesis and viral replication. TNF-ǂ is produced mainly by macrophages 
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but can also be produced by other cells including endothelial cells (Schutte et al, 1996). 
Large amounts of TNF-ǂ are released in response to LPS endotoxin, bacterial products and 
IL-1. TNF- ǂ works with IL-1 and IL-6 to produce actions on various organ systems (Schutte 
et al, 1996; Braun et al, 2005; Bauer et al, 2000). TNF-ǂ also induces EC activation and barrier 
dysfunction both of which occur in the pathogenesis of pulmonary edema and ALI/ARDS. 
It can promote edema by TNF receptor dependent chemokine production and adhesion 
molecule expression and leads to neutrophil chemotaxis (Braun et al, 2005; Ward, 1996). It 
also causes a decrease in transendothelial electrical resistance across human pulmonary 
artery EC (HPAEC) (Petrache et al 2003). The pulmonary capillary EC have a balanced 
system between contracting and tethering forces that normally act to protect the EC barrier 
from paracellular gaps. The balancing forces depend on cytoskeletal components such as 
actin based microfilaments, intermediate filaments and microtubules. TNF-ǂ causes 
contraction via the actin filaments and this results in the formation of gaps and EC 
permeability (Braun 2005). In pulmonary edema associated with ARDS, TNF-ǂ can mediate 
acute inflammation and edema formation. It can also have a beneficial effect by increasing 
alveolar fluid clearance via an amiloride sensitive, cAMP independent mechanism to 
enhance alveolar fluid clearance. This is accomplished by binding to its receptors or 
activating Na+ channels in the epithelium (Fukuda et al, 2001). 
Other networks of cytokines regulate lung inflammation in lung injury and edema. 
Complement, C5a and or the membrane attack complex, C5b-9 can directly activate EC to 
up-regulate adhesion molecules (P-selectin) or act synergistically with TNF-ǂ to up regulate 
I-CAM and E Selectin (Shutte et al, 1996 & Ward, 1996). IL-4 and IL-10 suppress TNF-ǂ and 
can have a strong attenuating effect on TNF-ǂ. Studies have shown that blocking IL-10 
increased TNF-ǂ production, neutrophil recruitment and the intensity of lung inflammation 
(Ward, 1996). Although the role of cytokines in the pathogenesis of ARDS has been widely 
recognized, their importance in the clinical diagnosis has not been clearly defined. 
Recent studies have identified that the receptor for advanced glycation end products 
(RAGE) is activated by its ligands in many disorders including ALI/ARDS. RAGE and 
interaction with the high mobility group box-1 (HMGB-1)- one of its ligands- promotes local 
lung endothelial inflammation and evokes both local and systemic inflammation 
(Nakamura et al, 2011 & Wolfson et al, 2010). In vitro studies determined that RAGE is the 
primary receptor signaling HMGB-1 induced endothelial barrier disruption and endothelial 
gap formation in human pulmonary artery endothelial cells (Wolfson et al, 2010). Soluable 
RAGE (sRAGE) has also been noted in the plasma of patients with ARDS and it was 
investigated as a biomarker of severity and clinical outcomes in patients with ARDS. In 
addition sRAGE and HMGB-1 levels were elevated in non- survivors compared to survivors 
in ARDS (Nakamura et al, 2011). An analysis of biomarker levels in two randomized 
controlled trials of ventilator therapy for ALI was done and the biomarkers that were 
elevated were ICAM-1, von Willebrand factor, IL-8, soluble TNF receptor-1, and surfactant 
protein-D. It was concluded that combining three or more biomarkers may be useful for 
selecting a high risk ALI group of patients (Calfee et al, 2011). Biomarker identification of 
risk remains an area of intense research. 
5. Non-inflammatory NCPE 
Categories of NCPE that resolve more quickly than ARDS and NCPE due to infection, 
trauma or other medical illness are high altitude pulmonary edema (HAPE), Immersion 
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pulmonary edema (SCUBA diving and swimming) and negative pressure pulmonary 
edema (NPPE). Most commonly the non-inflammatory forms of NCPE occur in baseline 
healthy people although there may be a predilection to development of pulmonary edema 
in some people. However, there is no known way to predict who will develop pulmonary 
edema and who will not in the same circumstances. 
 
Fig. 3. Schematic representation of the endothelial barrier in Non-inflammatory Pulmonary 
Edema 
Non- inflammatory pulmonary edema may have an element of hemorrhage leading to a 
pink frothy tint but will not initially have an inflammatory secretion of cells. The pulmonary 
edema resolves quickly and the endothelial barrier is thought to accommodate hydrostatic 
changes that resolve quickly compared to toxin mediated changes that heal slowly and may 
develop fibrinous changes. 
6. HAPE 
HAPE is a life threatening form of NCPE that has a rapid onset in healthy people who 
venture to elevations above 8200feet. This occurs when the lower barometric pressures 
result in hypoxia, usually less than 90% SPO2 or 60 PaO2. Studies done at high altitude on 
patients who developed HAPE and compared to those who did not, have shown that 
pulmonary artery pressures are elevated and lead to a protein rich and mildly hemorrhagic 
edema. Leukocytes, cytokines, nitric oxide metabolites and eicosanoids are normal when 
compared to control subjects who did not develop HAPE (Swenson et al, 2002). The 
mechanism of the increased pulmonary vasoconstriction and resulting increased pulmonary 
pressures is not resolved. The mechanism is thought to be increased pulmonary and arterial 
capillary pressures second to hypoxic pulmonary vasoconstriction. Another effect is a non-
inflammatory increase in the permeability of the vascular endothelium. Some people are 
more susceptible to HAPE than others but the differentiating factors are not known. The 
most important treatment is to descend as soon as possible and provide oxygen therapy. 
Other treatments are Dexamethasone and nifedipine. Phosphodiesterase inhibitors are 
effective but the side effects worsen mountain sickness headaches (Maggiorini, 2010).  
7. Immersion PE  
Immersion PE that occurs in diving with self contained underwater breathing apparatus 
(SCUBA), and some triathlon athletes, combat swimmers (such as found in military 
missions) and breath hold divers is another type of non-inflammatory NCPE. Only about 1-
2% of immersion divers develop PE and studies have not shown clearly what makes some 
people susceptible. One study did show that women, hypertension, fish oil and asthma may 
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be factors that predispose to this condition (Miller III et al, 2010). The mechanism is poorly 
understood but reviews of cases have shown that the onset is rapid and that rapid 
improvement is also seen, similar to patients who develop HAPE (Slade et al, 2001). This 
observation lends credence to the probability that this is an acute but transient increase in 
pressure. The stress from the increased transalveolar pressure gradient that occurs with 
immersion is such that the non-cardiogenic capillary endothelium layer cell develops leaks 
(Slade et al, 2001). It has been shown that even asymptomatic dives result in an increased 
accumulation of extravascular lung water (Marinovic et al, 2010). They further 
demonstrated an increase in lung water, pulmonary artery pressure, NT-proBNP levels and 
decreased left ventricular contractility in healthy study volunteers who did not develop 
pulmonary edema. Immersion is known to increase preload and cold exposure increases 
both preload and afterload by vasoconstriction; it is possible that the changes could lead to 
damage in the pulmonary endothelium and lead to intrapulmonary redistribution of blood 
with regional overperfusion of some pulmonary capillaries and stress failure increasing 
capillary damage and permeability (Marinovic et al, 2010 & Pons et al, 1995). Hyperoxia and 
low tank pressures are other possible mechanisms that may damage the pulmonary 
endothelium and increase endothelial permeability the development of pulmonary edema 
in immersion PE. 
8. Negative pressure pulmonary edema  
Negative pressure pulmonary edema (NPPE) is pulmonary edema that occurs following an 
acute upper airway obstruction and may also be referred to as a post obstructive pulmonary 
edema. It often occurs in otherwise healthy patients. The most common cause is 
laryngospasm soon after extubation from an endo-tracheal intubation in about 0.1% in post 
anesthesia patients (Pathak et al, 2011). There are also case reports of NPPE after other 
causes such as foreign body, epiglottitis, tracheal secretions, upper airway tumors, obesity, 
obstructive sleep apnea, tumors (Fremont et al, 2007). Following an episode of obstruction of 
the airway there is a marked increase in negative intrathoracic pressure against the 
obstructed upper airway. The rapid increase in intrathoracic pressure causes a rise in 
venous return to the right heart, which increases pulmonary venous volume and pulmonary 
venous pressure which then increases the pulmonary capillary transmural pressure. 
Systemic pressures also rise due to catecholamine induced veno-constriction from anxiety, 
hypoxia and hypercarbia (Schwartz et al, 1999). Fremont et al have shown that the 
mechanism is due to hydrostatic changes with the fluid moving from high pressure in the 
pulmonary venous system to low pressure into the pulmonary interstitium and airspaces. 
Studies confirmed that the pulmonary edema fluid to plasma protein ratio were consistent 
with hydrostatic causes of acute fluid shifts and pulmonary edema. This causes an increase 
of blood flow (venous return) to the right heart increasing pulmonary venous pressure 
(Fremont et al, 2007). The treatment is resolving the obstruction, oxygen and either 
reintubation or if the patient is stable CPAP may be used. The issue is not volume overload 
and diuretics are not indicated (Kapoor, 2011). 
9. Clinical manifestation of non cardiogenic pulmonary edema 
Clinically non-cardiogenic pulmonary edema is a permeability edema. The Starling equation 
predicts that a change in permeability of the microvascular membrane will result in an 
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increase in the amount of fluid and protein that leaves the vascular space and enters the 
interstitial space. When the interstitial fluid increases in the interstitium then the outward 
movement continues and fluid enters the alveolar spaces through the tight junctions of the 
epithelium. Many entities are associated with permeability edema manifested as ARDS, the 
most common entities are sepsis, pneumonia, multiple blood transfusions, gastric 
aspiration, trauma, drug overdose and pancreatitis.  and others. Clinically NCPE prototype 
ALI/ARDS presents with progressive hypoxia and respiratory failure. Multi-organ failure is 
frequent and one of the reasons the mortality is so high. ARDS affects 200,000 people per 
year and has a mortality rate of 30-50%. This was initially described in the 1960s’ by Petty 
and Ashbaugh (Ashbaugh et al, 1967). The diagnosis is made by four clinical criteria, acute 
onset of bilateral chest infiltrates, hypoxia, no evidence of left atrial hypertension (or clinical 
manifestations indicating left heart failure) and a ratio of arterial oxygen to fraction of 
inspired oxygen (PaO2/FIO2 ratio) of 201-300 for ALI and less than 200 for ARDS (Bernard 
et al, 1994 & The Acute Respiratory Distress Syndrome Network, 2000). Due to the profound 
respiratory failure most patients require mechanical ventilation and care in the intensive 
care unit (ICU). The best therapeutic approach for ARDS permeability edema is to find and 
treat the cause. There is no pharmacological treatment for ARDS, the only “treatment” that 
has emerged since it was first described in 1971 is the ARDS-net trial protocol of low tidal 
volume mechanical ventilation. This is a strategy that is called “lung-protective ventilation”. 
The main benefit of lung-protective ventilation is to avoid further injury to the lungs from 
high tidal volumes often used for patients in the ICU as these large tidal volumes increase 
the injury and subsequently cause an increase in the permeability pulmonary edema in the 
injured lung. The standard tidal volumes used in ICU have been 10-15mg/kg for all 
mechanically ventilated patients, however, low tidal volumes of 6-8mg/kg are 
recommended for patients with ARDS. A mortality benefit was one of the primary outcomes 
demonstrated in the ARDS-net trial for patients with ARDS who are mechanically ventilated 
at these low tidal volumes (Matthay et al, 2002 & Marino 2007). Another aspect of NCPE and 
ARDS is heterogeneity of the lung parenchyma and the alveoli. The chest roentgenogram 
shows bilateral infiltrates that are difficult to distinguish from cardiogenic pulmonary 
edema and sometimes from pneumonia. The computed tomographic (CT) images are not 
necessarily diagnostic but in a patient with known ARDS shows that the lung edema and 
consolidation is not homogeneous but involves various lung regions, while other regions 
appear normal (Rouby et al, 2003). Alveolar over-distension from mechanical ventilation as 
well as repeated opening and collapse of the alveoli has been shown to cause lung injury 
initiating an increase in capillary stress and an increase in pro-inflammatory cytokine 
cascades (Matthay et al, 2002 & Slutsky &Tremblay, 1998). Hemodynamic evaluation of 
NCPE and ARDS requires careful ongoing evaluation, and may require monitoring cardiac 
filling pressures and cardiac output using a pulmonary artery catheter or currently, a non-
invasive evaluation is more likely to be used. Diuretic therapy is then tailored to achieve the 
lowest cardiac filling pressures that do not compromise cardiac output and systemic oxygen 
transport. The nature of the lung interstitial infiltration is an inflammatory process, so that 
diuretic therapy to remove fluid does not remove the inflammation. Fluid treatment versus 
diuresis is not necessarily the goal of treatment in NCPE secondary to ARDS (Marino, 2007). 
Ultimately the treatment is supportive care using the appropriate ventilator strategies, 
promoting oxygenation, and treating the multi organ failure that is often contributes to the 
mortality. Histologically in this acute phase of lung injury there is widespread interstitial 
and alveolar edema with an abundance of neutrophils, erythrocytes, macrophages, cell 
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debris, plasma proteins and strands of fibrin. At this phase there is injury to the capillary 
endothelium and denuding of the alveolar epithelium. If the patient survives this phase the 
pulmonary edema may completely resolve within a few months. Other patients with 
ALI/ARDS progress to a subacute phase over one to two weeks and may continue to have 
respiratory failure with hypoxia requiring mechanical ventilation. These patients develop 
fibrosis and capillary obliteration in the lungs, a condition called fibrosing alveolitis. These 
patients continue to progress with respiratory failure although they may recover from the 
initial event.  
Progress from bench to bedside is being made; the mortality from NCPE and ALI/ARDS 
has improved from the initial 60% or more to 30-50%. The establishment of the NIH ARDS 
Network for clinical trials has improved the quantity and quality of large multicenter 
clinical trials for ALI/ARDS patients. New research is continuing and tools such as genetic 
analysis, genomics and proteomics may offer more value for patients in the future. 
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